TY - JOUR
T1 - Effects of zinc and manganese on advanced glycation end products (AGEs) formation and AGEs-mediated endothelial cell dysfunction
AU - Zhuang, Xiuyuan
AU - Pang, Xiufeng
AU - Zhang, Wen
AU - Wu, Wenbin
AU - Zhao, Jingjing
AU - Yang, Huangjian
AU - Qu, Weijing
PY - 2012/1/16
Y1 - 2012/1/16
N2 - Aims: The present study investigated the effects of ZnCl 2 and MnCl 2 supplementations on advanced glycation end products (AGEs) formation and AGEs-mediated endothelial cell dysfunction. Main methods: Fluorescence detection was used to monitor the Maillard reaction. Inductively coupled plasma optical emission spectroscopy was used to test cellular zinc and manganese levels. Real-time reverse transcription polymerase chain reaction and western blot were used to analyze the expression of endothelial nitric oxide synthase (eNOS), nuclear transcription factor kappa B (NF-κB), and receptor for AGEs (RAGE). Intracellular reactive oxygen species (ROS) and nitric oxide (NO) production, NOS activity were determined by fluorescent probe assay, superoxide dismutase (SOD) activity was determined by water soluble tetrazolium salt assay. Key findings: MnCl 2 showed excellent inhibitory effect on AGEs formation. Primary cultured bovine aortic endothelial cells (BAECs) were exposed to AGEs for 30 min, followed by trace element treatments. Cell viability and the zinc levels declined due to AGEs exposure, which were improved with the supplementations of ZnCl 2 and MnCl 2. Furthermore, ZnCl 2 supplementation effectively enhanced intracellular NO production, elevated eNOS expression and enzymatic activity, and down-regulated NF-κB activation and RAGE expression. MnCl 2 dose-dependently impaired ROS formation, down-regulated NF-κB protein expression and nuclear translocation, as well as restored Mn-SOD enzymatic capability. Significance: Our findings suggested that trace elements relevant to diabetic, such as zinc and manganese played different roles in the formation of AGEs. Both the elements benefited the AGEs-injured BAECs through different mechanisms.
AB - Aims: The present study investigated the effects of ZnCl 2 and MnCl 2 supplementations on advanced glycation end products (AGEs) formation and AGEs-mediated endothelial cell dysfunction. Main methods: Fluorescence detection was used to monitor the Maillard reaction. Inductively coupled plasma optical emission spectroscopy was used to test cellular zinc and manganese levels. Real-time reverse transcription polymerase chain reaction and western blot were used to analyze the expression of endothelial nitric oxide synthase (eNOS), nuclear transcription factor kappa B (NF-κB), and receptor for AGEs (RAGE). Intracellular reactive oxygen species (ROS) and nitric oxide (NO) production, NOS activity were determined by fluorescent probe assay, superoxide dismutase (SOD) activity was determined by water soluble tetrazolium salt assay. Key findings: MnCl 2 showed excellent inhibitory effect on AGEs formation. Primary cultured bovine aortic endothelial cells (BAECs) were exposed to AGEs for 30 min, followed by trace element treatments. Cell viability and the zinc levels declined due to AGEs exposure, which were improved with the supplementations of ZnCl 2 and MnCl 2. Furthermore, ZnCl 2 supplementation effectively enhanced intracellular NO production, elevated eNOS expression and enzymatic activity, and down-regulated NF-κB activation and RAGE expression. MnCl 2 dose-dependently impaired ROS formation, down-regulated NF-κB protein expression and nuclear translocation, as well as restored Mn-SOD enzymatic capability. Significance: Our findings suggested that trace elements relevant to diabetic, such as zinc and manganese played different roles in the formation of AGEs. Both the elements benefited the AGEs-injured BAECs through different mechanisms.
KW - Advanced glycation end products
KW - Endothelial cells
KW - Manganese
KW - Nitric oxide
KW - Nuclear factor kappa B
KW - Reactive oxygen species
KW - Zinc
UR - https://www.scopus.com/pages/publications/84855324380
U2 - 10.1016/j.lfs.2011.10.025
DO - 10.1016/j.lfs.2011.10.025
M3 - 文章
C2 - 22100512
AN - SCOPUS:84855324380
SN - 0024-3205
VL - 90
SP - 131
EP - 139
JO - Life Sciences
JF - Life Sciences
IS - 3-4
ER -